Item 1.02. Termination of a Material Definitive Agreement.
On September 23, 2022, Incyte Corporation notified Calithera Biosciences, Inc.,
of its intent to terminate for convenience that certain Collaboration and
License Agreement, by and between Incyte and Calithera Biosciences, dated
January 27, 2017, or the Collaboration and License Agreement. The termination
will be effective on or about December 28, 2022. No material early termination
penalties will be payable by either party.
The Collaboration and License Agreement is filed as exhibit 10.1 to our
Quarterly Report on Form 10-Q, for the three months ended March 31, 2017 (File
No. 001-36644), filed with the Securities and Exchange Commission on May 9,
2017. For a summary of the material terms of the Collaboration and License
Agreement please see " Part I, Item 1. Business - Partnered Programs - Arginase
Inhibitor INCB001158 for Oncology " of our Annual Report on Form 10-K for the
year ended December 31, 2021 (File No. 001-36644), filed with the Securities and
Exchange Commission on March 31, 2022, which summary is incorporated herein.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses